← Back to patent-cliff list

CAS 109-73-9

1-AminobutaneButylamineMonobutylaminebutan-1-amine

Codes: (VII)101438-62-a, Tetracaine-016, DX1002-004, PT-2385-018

Application context (from source-drug indications)

Breast cancerPaclitaxel/Encequidar mesylateAdenocarcinomaPaclitaxel/Encequidar mesylateAngiosarcomaPaclitaxel/Encequidar mesylateSolid tumourPaclitaxel/Encequidar mesylateAnaesthesiaOxymetazoline Hydrochloride/Tetracaine HydrochloridePeriapical periodontitisOxymetazoline Hydrochloride/Tetracaine HydrochlorideDental cariesOxymetazoline Hydrochloride/Tetracaine HydrochloridePancreatic cancerPaclitaxelNon-small cell lung cancerPaclitaxelHodgkin's diseasePaclitaxelSeminomaPaclitaxelOvarian cancerPaclitaxelBreast cancerPaclitaxelAnaesthesiaTetracaine HydrochlorideRetinitis pigmentosaTetracaine HydrochloridePainTetracaine HydrochlorideHepatocellular carcinomaDX1002食管胃结合部肿瘤DX1002Gastric cancerDX1002Liver cancerDX1002Solid tumourDX1002von Hippel-Lindau syndromePT-2385SarcomaPT-2385Renal cell carcinomaPT-2385肾肿瘤PT-2385GlioblastomaPT-2385

Source drugs (routes using this intermediate)

DrugTierExpiry
Paclitaxel/Encequidar mesylateTier C — Watch / trade-
Oxymetazoline Hydrochloride/Tetracaine HydrochlorideTier C — Watch / trade-
PaclitaxelTier B — Position early-
Tetracaine HydrochlorideTier C — Watch / trade-
DX1002Tier C — Watch / trade-
PT-2385Tier C — Watch / trade-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

Intermediates available on this site

No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.